VistaGen Therapeutics Inc. (NASDAQ:VTGN) went down by -4.35% from its latest closing price compared to the recent 1-year high of $3.18. The company’s stock price has collected -2.34% of loss in the last five trading sessions. Press Release reported on 03/22/21 that VistaGen’s Poster Presentation at the Anxiety and Depression Association of America’s 2021 Annual Conference Differentiates PH94B’s Mechanism of Action from Highly-Addictive Benzodiazepines
Is It Worth Investing in VistaGen Therapeutics Inc. (NASDAQ :VTGN) Right Now?
Plus, the 36-month beta value for VTGN is at 0.82. Opinions of the stock are interesting as 2 analysts out of 2 who provided ratings for VistaGen Therapeutics Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $6.00. VTGN currently public float of 109.42M and currently shorts hold a 8.44% ratio of that float. Today, the average trading volume of VTGN was 3.56M shares.
VTGN’s Market Performance
VTGN stocks went down by -2.34% for the week, with a monthly drop of -0.48% and a quarterly performance of 1.95%, while its annual performance rate touched 422.50%. The volatility ratio for the week stands at 7.26% while the volatility levels for the past 30 days are set at 8.05% for VistaGen Therapeutics Inc.. The simple moving average for the period of the last 20 days is -5.80% for VTGN stocks with a simple moving average of 70.49% for the last 200 days.
Analysts’ Opinion of VTGN
Many brokerage firms have already submitted their reports for VTGN stocks, with Jefferies repeating the rating for VTGN by listing it as a “Buy.” The predicted price for VTGN in the upcoming period, according to Jefferies is $6 based on the research report published on February 18th of the current year 2021.
Maxim Group gave a rating of “Buy” to VTGN, setting the target price at $6 in the report published on June 27th of the previous year.
VTGN Trading at -5.91% from the 50-Day Moving Average
After a stumble in the market that brought VTGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -34.28% of loss for the given period.
Volatility was left at 8.05%, however, over the last 30 days, the volatility rate increased by 7.26%, as shares sank -6.70% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -18.04% lower at present.
During the last 5 trading sessions, VTGN fell by -2.34%, which changed the moving average for the period of 200-days by +307.88% in comparison to the 20-day moving average, which settled at $2.21. In addition, VistaGen Therapeutics Inc. saw 7.73% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at VTGN starting from SAXE JON S, who purchase 30,000 shares at the price of $0.69 back on Aug 21. After this action, SAXE JON S now owns 50,000 shares of VistaGen Therapeutics Inc., valued at $20,700 using the latest closing price.
Stock Fundamentals for VTGN
The total capital return value is set at -725.79, while invested capital returns managed to touch -819.37. Equity return is now at value -75.50, with -46.20 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 0.57.